^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vevoctadekin (ST-067)

    i
    Other names: ST-067, engineered variant of human interleukin-18, human variant of DR-18, human variant of decoy-resistant IL-18, ST067, ST 067
    Associations

    News

    Trials
    Company:
    Simcha Therap
    Drug class:
    IL-18 stimulant
    Related drugs:
    Associations

    News

    Trials
    2ms
    ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=33, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Breyanzi (lisocabtagene maraleucel) • vevoctadekin (ST-067)
    4ms
    ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=33, Not yet recruiting, Fred Hutchinson Cancer Center
    New P1/2 trial
    |
    Breyanzi (lisocabtagene maraleucel) • vevoctadekin (ST-067)
    4ms
    ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=1, Terminated, University of Washington | N=20 --> 1 | Trial completion date: Dec 2026 --> Feb 2025 | Recruiting --> Terminated | Trial primary completion date: Mar 2026 --> Feb 2025; Study terminated due to end of funding.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Tecvayli (teclistamab-cqyv) • vevoctadekin (ST-067)
    6ms
    DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial (clinicaltrials.gov)
    P1, N=20, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: May 2027 --> Oct 2027 | Trial primary completion date: May 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    vevoctadekin (ST-067)
    1year
    ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=20, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tecvayli (teclistamab-cqyv) • vevoctadekin (ST-067)
    1year
    KEYNOTE-E64: Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 (clinicaltrials.gov)
    P1/2, N=316, Recruiting, Simcha IL-18, Inc. | Active, not recruiting --> Recruiting | Trial completion date: Jan 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Jun 2025
    Enrollment open • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • Gazyva (obinutuzumab) • vevoctadekin (ST-067)
    1year
    ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, University of Washington
    New P1 trial
    |
    Tecvayli (teclistamab-cqyv) • vevoctadekin (ST-067)
    1year
    DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial (clinicaltrials.gov)
    P1, N=20, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    vevoctadekin (ST-067)
    over1year
    KEYNOTE-E64: Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 (clinicaltrials.gov)
    P1/2, N=316, Active, not recruiting, Simcha IL-18, Inc. | Recruiting --> Active, not recruiting | Phase classification: P1a --> P1/2 | Trial primary completion date: Jun 2024 --> Sep 2024
    Enrollment closed • Phase classification • Trial primary completion date • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    Keytruda (pembrolizumab) • Gazyva (obinutuzumab) • vevoctadekin (ST-067)
    over1year
    DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, University of Washington
    New P1 trial
    |
    vevoctadekin (ST-067)
    2years
    A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies (SITC 2023)
    1. Recruitment is ongoing in the US.
    Clinical • P1/2 data • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    IL18 (Interleukin 18)
    |
    Keytruda (pembrolizumab) • vevoctadekin (ST-067)
    over2years
    Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 (clinicaltrials.gov)
    P1a, N=316, Recruiting, Simcha IL-18, Inc. | N=198 --> 316
    Enrollment change • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • Gazyva (obinutuzumab) • vevoctadekin (ST-067)